Simplifying HIV Treatment: A Shift towards Single-Tablet Regimens and Improved Patient Satisfaction
Original framing: “[Articles] Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial” — The Lancet
The development of antiretroviral therapy for HIV is a significant milestone in the history of medicine, marking a major shift towards effective treatment and management of the disease. However, the history of HIV treatment is also marked by controversy and activism, including the struggle for access to treatment and the development of treatment as prevention.
The ARTISTRY-1 trial highlights the potential of bictegravir–lenacapavir as a simplified treatment option for HIV-1 patients, offering non-inferior efficacy and improved treatment satisfaction compared to complex regimens.
However, the narrative neglects the perspectives of marginalized communities and the structural causes of healthcare disparities. To address these gaps, community-based initiatives and partnerships with healthcare providers can be scaled up to reach marginalized populations, while addressing the structural causes of healthcare disparities through policy and programmatic interventions. Ultimately, a nuanced and context-specific approach to HIV treatment is essential to improving treatment outcomes and reducing healthcare costs.